IBDEI0GM ; ; 01-FEB-2022
;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
Q:'DIFQR(358.3) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.3,7457,0)
;;=C7A.029^^36^368^31
;;^UTILITY(U,$J,358.3,7457,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7457,1,3,0)
;;=3^Carcinoid,Malignant,Unspec Colon
;;^UTILITY(U,$J,358.3,7457,1,4,0)
;;=4^C7A.029
;;^UTILITY(U,$J,358.3,7457,2)
;;=^5001370
;;^UTILITY(U,$J,358.3,7458,0)
;;=C7B.02^^36^368^5
;;^UTILITY(U,$J,358.3,7458,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7458,1,3,0)
;;=3^Carcinoid of Liver
;;^UTILITY(U,$J,358.3,7458,1,4,0)
;;=4^C7B.02
;;^UTILITY(U,$J,358.3,7458,2)
;;=^5001383
;;^UTILITY(U,$J,358.3,7459,0)
;;=E34.0^^36^368^6
;;^UTILITY(U,$J,358.3,7459,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7459,1,3,0)
;;=3^Carcinoid syndrome
;;^UTILITY(U,$J,358.3,7459,1,4,0)
;;=4^E34.0
;;^UTILITY(U,$J,358.3,7459,2)
;;=^19261
;;^UTILITY(U,$J,358.3,7460,0)
;;=C83.79^^36^368^33
;;^UTILITY(U,$J,358.3,7460,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7460,1,3,0)
;;=3^Lymphoma,Burkitt,Extranodal
;;^UTILITY(U,$J,358.3,7460,1,4,0)
;;=4^C83.79
;;^UTILITY(U,$J,358.3,7460,2)
;;=^5001600
;;^UTILITY(U,$J,358.3,7461,0)
;;=C83.39^^36^368^34
;;^UTILITY(U,$J,358.3,7461,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7461,1,3,0)
;;=3^Lymphoma,Diffuse large B-Cell,Extranodal
;;^UTILITY(U,$J,358.3,7461,1,4,0)
;;=4^C83.39
;;^UTILITY(U,$J,358.3,7461,2)
;;=^5001580
;;^UTILITY(U,$J,358.3,7462,0)
;;=C86.2^^36^368^35
;;^UTILITY(U,$J,358.3,7462,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7462,1,3,0)
;;=3^Lymphoma,Enteropathy T-cell type
;;^UTILITY(U,$J,358.3,7462,1,4,0)
;;=4^C86.2
;;^UTILITY(U,$J,358.3,7462,2)
;;=^5001743
;;^UTILITY(U,$J,358.3,7463,0)
;;=C82.59^^36^368^36
;;^UTILITY(U,$J,358.3,7463,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7463,1,3,0)
;;=3^Lymphoma,Follicular Diffuse,Extranodal
;;^UTILITY(U,$J,358.3,7463,1,4,0)
;;=4^C82.59
;;^UTILITY(U,$J,358.3,7463,2)
;;=^5001520
;;^UTILITY(U,$J,358.3,7464,0)
;;=C88.4^^36^368^37
;;^UTILITY(U,$J,358.3,7464,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7464,1,3,0)
;;=3^Lymphoma,MALT Type
;;^UTILITY(U,$J,358.3,7464,1,4,0)
;;=4^C88.4
;;^UTILITY(U,$J,358.3,7464,2)
;;=^5001749
;;^UTILITY(U,$J,358.3,7465,0)
;;=C83.19^^36^368^38
;;^UTILITY(U,$J,358.3,7465,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7465,1,3,0)
;;=3^Lymphoma,Mantle cell,Extranodal
;;^UTILITY(U,$J,358.3,7465,1,4,0)
;;=4^C83.19
;;^UTILITY(U,$J,358.3,7465,2)
;;=^5001570
;;^UTILITY(U,$J,358.3,7466,0)
;;=C78.6^^36^368^39
;;^UTILITY(U,$J,358.3,7466,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7466,1,3,0)
;;=3^Peritoneal carinomatosis
;;^UTILITY(U,$J,358.3,7466,1,4,0)
;;=4^C78.6
;;^UTILITY(U,$J,358.3,7466,2)
;;=^108899
;;^UTILITY(U,$J,358.3,7467,0)
;;=E85.89^^36^368^3
;;^UTILITY(U,$J,358.3,7467,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7467,1,3,0)
;;=3^Amyloidosis,Systemic
;;^UTILITY(U,$J,358.3,7467,1,4,0)
;;=4^E85.89
;;^UTILITY(U,$J,358.3,7467,2)
;;=^334034
;;^UTILITY(U,$J,358.3,7468,0)
;;=E85.81^^36^368^1
;;^UTILITY(U,$J,358.3,7468,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7468,1,3,0)
;;=3^Amyloidosis,Light Chain (AL)
;;^UTILITY(U,$J,358.3,7468,1,4,0)
;;=4^E85.81
;;^UTILITY(U,$J,358.3,7468,2)
;;=^5151302
;;^UTILITY(U,$J,358.3,7469,0)
;;=E85.82^^36^368^4
;;^UTILITY(U,$J,358.3,7469,1,0)
;;=^358.31IA^4^2
;;^UTILITY(U,$J,358.3,7469,1,3,0)
;;=3^Amyloidosis,Wild-type Transthyretin-related (ATTR)
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI0GM 3745 printed Sep 23, 2025@19:24:17 Page 2
IBDEI0GM ; ; 01-FEB-2022
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
+2 if 'DIFQR(358.3)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,999)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.3,7457,0)
+2 ;;=C7A.029^^36^368^31
+3 ;;^UTILITY(U,$J,358.3,7457,1,0)
+4 ;;=^358.31IA^4^2
+5 ;;^UTILITY(U,$J,358.3,7457,1,3,0)
+6 ;;=3^Carcinoid,Malignant,Unspec Colon
+7 ;;^UTILITY(U,$J,358.3,7457,1,4,0)
+8 ;;=4^C7A.029
+9 ;;^UTILITY(U,$J,358.3,7457,2)
+10 ;;=^5001370
+11 ;;^UTILITY(U,$J,358.3,7458,0)
+12 ;;=C7B.02^^36^368^5
+13 ;;^UTILITY(U,$J,358.3,7458,1,0)
+14 ;;=^358.31IA^4^2
+15 ;;^UTILITY(U,$J,358.3,7458,1,3,0)
+16 ;;=3^Carcinoid of Liver
+17 ;;^UTILITY(U,$J,358.3,7458,1,4,0)
+18 ;;=4^C7B.02
+19 ;;^UTILITY(U,$J,358.3,7458,2)
+20 ;;=^5001383
+21 ;;^UTILITY(U,$J,358.3,7459,0)
+22 ;;=E34.0^^36^368^6
+23 ;;^UTILITY(U,$J,358.3,7459,1,0)
+24 ;;=^358.31IA^4^2
+25 ;;^UTILITY(U,$J,358.3,7459,1,3,0)
+26 ;;=3^Carcinoid syndrome
+27 ;;^UTILITY(U,$J,358.3,7459,1,4,0)
+28 ;;=4^E34.0
+29 ;;^UTILITY(U,$J,358.3,7459,2)
+30 ;;=^19261
+31 ;;^UTILITY(U,$J,358.3,7460,0)
+32 ;;=C83.79^^36^368^33
+33 ;;^UTILITY(U,$J,358.3,7460,1,0)
+34 ;;=^358.31IA^4^2
+35 ;;^UTILITY(U,$J,358.3,7460,1,3,0)
+36 ;;=3^Lymphoma,Burkitt,Extranodal
+37 ;;^UTILITY(U,$J,358.3,7460,1,4,0)
+38 ;;=4^C83.79
+39 ;;^UTILITY(U,$J,358.3,7460,2)
+40 ;;=^5001600
+41 ;;^UTILITY(U,$J,358.3,7461,0)
+42 ;;=C83.39^^36^368^34
+43 ;;^UTILITY(U,$J,358.3,7461,1,0)
+44 ;;=^358.31IA^4^2
+45 ;;^UTILITY(U,$J,358.3,7461,1,3,0)
+46 ;;=3^Lymphoma,Diffuse large B-Cell,Extranodal
+47 ;;^UTILITY(U,$J,358.3,7461,1,4,0)
+48 ;;=4^C83.39
+49 ;;^UTILITY(U,$J,358.3,7461,2)
+50 ;;=^5001580
+51 ;;^UTILITY(U,$J,358.3,7462,0)
+52 ;;=C86.2^^36^368^35
+53 ;;^UTILITY(U,$J,358.3,7462,1,0)
+54 ;;=^358.31IA^4^2
+55 ;;^UTILITY(U,$J,358.3,7462,1,3,0)
+56 ;;=3^Lymphoma,Enteropathy T-cell type
+57 ;;^UTILITY(U,$J,358.3,7462,1,4,0)
+58 ;;=4^C86.2
+59 ;;^UTILITY(U,$J,358.3,7462,2)
+60 ;;=^5001743
+61 ;;^UTILITY(U,$J,358.3,7463,0)
+62 ;;=C82.59^^36^368^36
+63 ;;^UTILITY(U,$J,358.3,7463,1,0)
+64 ;;=^358.31IA^4^2
+65 ;;^UTILITY(U,$J,358.3,7463,1,3,0)
+66 ;;=3^Lymphoma,Follicular Diffuse,Extranodal
+67 ;;^UTILITY(U,$J,358.3,7463,1,4,0)
+68 ;;=4^C82.59
+69 ;;^UTILITY(U,$J,358.3,7463,2)
+70 ;;=^5001520
+71 ;;^UTILITY(U,$J,358.3,7464,0)
+72 ;;=C88.4^^36^368^37
+73 ;;^UTILITY(U,$J,358.3,7464,1,0)
+74 ;;=^358.31IA^4^2
+75 ;;^UTILITY(U,$J,358.3,7464,1,3,0)
+76 ;;=3^Lymphoma,MALT Type
+77 ;;^UTILITY(U,$J,358.3,7464,1,4,0)
+78 ;;=4^C88.4
+79 ;;^UTILITY(U,$J,358.3,7464,2)
+80 ;;=^5001749
+81 ;;^UTILITY(U,$J,358.3,7465,0)
+82 ;;=C83.19^^36^368^38
+83 ;;^UTILITY(U,$J,358.3,7465,1,0)
+84 ;;=^358.31IA^4^2
+85 ;;^UTILITY(U,$J,358.3,7465,1,3,0)
+86 ;;=3^Lymphoma,Mantle cell,Extranodal
+87 ;;^UTILITY(U,$J,358.3,7465,1,4,0)
+88 ;;=4^C83.19
+89 ;;^UTILITY(U,$J,358.3,7465,2)
+90 ;;=^5001570
+91 ;;^UTILITY(U,$J,358.3,7466,0)
+92 ;;=C78.6^^36^368^39
+93 ;;^UTILITY(U,$J,358.3,7466,1,0)
+94 ;;=^358.31IA^4^2
+95 ;;^UTILITY(U,$J,358.3,7466,1,3,0)
+96 ;;=3^Peritoneal carinomatosis
+97 ;;^UTILITY(U,$J,358.3,7466,1,4,0)
+98 ;;=4^C78.6
+99 ;;^UTILITY(U,$J,358.3,7466,2)
+100 ;;=^108899
+101 ;;^UTILITY(U,$J,358.3,7467,0)
+102 ;;=E85.89^^36^368^3
+103 ;;^UTILITY(U,$J,358.3,7467,1,0)
+104 ;;=^358.31IA^4^2
+105 ;;^UTILITY(U,$J,358.3,7467,1,3,0)
+106 ;;=3^Amyloidosis,Systemic
+107 ;;^UTILITY(U,$J,358.3,7467,1,4,0)
+108 ;;=4^E85.89
+109 ;;^UTILITY(U,$J,358.3,7467,2)
+110 ;;=^334034
+111 ;;^UTILITY(U,$J,358.3,7468,0)
+112 ;;=E85.81^^36^368^1
+113 ;;^UTILITY(U,$J,358.3,7468,1,0)
+114 ;;=^358.31IA^4^2
+115 ;;^UTILITY(U,$J,358.3,7468,1,3,0)
+116 ;;=3^Amyloidosis,Light Chain (AL)
+117 ;;^UTILITY(U,$J,358.3,7468,1,4,0)
+118 ;;=4^E85.81
+119 ;;^UTILITY(U,$J,358.3,7468,2)
+120 ;;=^5151302
+121 ;;^UTILITY(U,$J,358.3,7469,0)
+122 ;;=E85.82^^36^368^4
+123 ;;^UTILITY(U,$J,358.3,7469,1,0)
+124 ;;=^358.31IA^4^2
+125 ;;^UTILITY(U,$J,358.3,7469,1,3,0)
+126 ;;=3^Amyloidosis,Wild-type Transthyretin-related (ATTR)
